The Pharma Data

NOVEMBER 1, 2020

The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Clinical Pharmacology 52

Clinical Pharmacology Small Molecule Clinical Research Science 52

New Drug Approvals

SEPTEMBER 13, 2024

30 January 2018. “LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders” Neuropharmacology. Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ (March 2018). McHugh KL, Kelly JP (2018).

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Agency IQ

OCTOBER 6, 2023

This is a significant jump from any previous year, with the former peak at 15 in FY 2018, followed by several years in the 10-14 range. For example, these products face a much more arduous path for development of biosimilar or interchangeable products than that of generics for small molecules.

FDA 52

FDA Biosimilars Science Drugs 52